Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 11201 | Palmetto GBA | A and B and HHH MAC | SC |
| 11301 | Palmetto GBA | A and B and HHH MAC | VA |
| 11401 | Palmetto GBA | A and B and HHH MAC | WV |
| 11501 | Palmetto GBA | A and B and HHH MAC | NC |
| 11202 | Palmetto GBA | A and B and HHH MAC | SC |
| 11302 | Palmetto GBA | A and B and HHH MAC | VA |
| 11402 | Palmetto GBA | A and B and HHH MAC | WV |
| 11502 | Palmetto GBA | A and B and HHH MAC | NC |
| 10111 | Palmetto GBA | A and B MAC | AL |
| 10211 | Palmetto GBA | A and B MAC | GA |
| 10311 | Palmetto GBA | A and B MAC | TN |
| 10112 | Palmetto GBA | A and B MAC | AL |
| 10212 | Palmetto GBA | A and B MAC | GA |
| 10312 | Palmetto GBA | A and B MAC | TN |
Billing and coding article A56718: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56718 (Billing and Coding: Intravenous Immunoglobulin (IVIG)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A56718: Billing and Coding: Intravenous Immunoglobulin (IVIG) (Billing and Coding, effective 2026-07-01)
- Covered ICD-10-CM codes
- 212
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 13
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| A85.8 | Other specified viral encephalitis |
| B08.3 | Erythema infectiosum [fifth disease] |
| B20 | Human immunodeficiency virus [HIV] disease |
| B25.0 | Cytomegaloviral pneumonitis |
| B25.1 | Cytomegaloviral hepatitis |
| B25.2 | Cytomegaloviral pancreatitis |
| B25.8 | Other cytomegaloviral diseases |
| B25.9 | Cytomegaloviral disease, unspecified |
| C88.00 | Waldenstrom macroglobulinemia not having achieved remission |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C91.11 | Chronic lymphocytic leukemia of B-cell type in remission |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse |
| D47.3 | Essential (hemorrhagic) thrombocythemia |
| D55.0 | Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency |
| D55.1 | Anemia due to other disorders of glutathione metabolism |
| D55.21 | Anemia due to pyruvate kinase deficiency |
| D55.29 | Anemia due to other disorders of glycolytic enzymes |
| D55.3 | Anemia due to disorders of nucleotide metabolism |
| D55.8 | Other anemias due to enzyme disorders |
| D55.9 | Anemia due to enzyme disorder, unspecified |
| D56.0 | Alpha thalassemia |
| D56.1 | Beta thalassemia |
Procedure codes: J1459 (Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1552 (Injection, immune globulin (alyglo), 500 mg), J1554 (Injection, immune globulin (asceniv), 500 mg), J1556 (Injection, immune globulin (bivigam), 500 mg), J1557 (Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1561 (Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg), J1566 (Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg), J1568 (Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1569 (Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg), J1576 (Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1599 (Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg), J2791 (Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu), J2792 (Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu).
Coverage indications, limitations and medical necessity
Intravenous Immune Globulin (IVIG) is a solution of human immunoglobulins specifically prepared for intravenous infusion. Immunoglobulins contain a broad range of antibodies that act specifically against bacterial and viral antigens.
INDICATIONS:
• Treatment of primary immunodeficiency syndromes associated with defects in humoral immunity to replace or boost immunoglobulin G (IgG)
• Treatment of idiopathic thrombocytopenic purpura (ITP) when a rapid rise in the platelet count is required such as prior to surgery, to control excessive bleeding, or to defer or avoid splenectomy
• Treatment of Kawasaki disease, in conjunction with aspirin
• Prevention of recurrent bacterial infections in patients with hypogammaglobulinemia associated with B-cell chronic lymphocytic leukemia (CLL)
• Decreasing risk of acute graft versus host disease, associated interstitial pneumonia, and infections after bone marrow transplant in the first 100 days after transplantation
• Reducing the risk of severe bacterial infections in human immunodeficiency virus (HIV) infected children with a CD4 count of greater than 200 to 400
• Second-line treatment of certain autoimmune myopathies
• Treatment of adults with Guillain-Barr é syndrome diagnosed within the first 2 weeks of illness
• Treatment of hyperimmunoglobulinemia E syndrome and Lambert-Eaton myasthenic syndrome (LEMS)
• Treatment of multifocal motor neuropathy (MMN)
• Treatment of relapsing-remitting multiple sclerosis
• Treatment of chronic parvovirus B19 infection and severe anemia associated with bone marrow suppression and pure red cell aplasia
• Treatment of progressive pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita in patients that have failed conventional treatment and patients in whom conventional therapy is otherwise contraindicated
• For coverage criteria of autoimmune mucocutaneous blistering diseases, please see CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §250.3
• Treatment of stiff person syndrome
• Treatment of myasthenia gravis (MG) in patients who have profound, rapidly progressive and/or potentially life-threatening muscular weakness and are refractory to, or intolerant of cholinesterase inhibitors, corticosteroids and azathioprine
• Prevention and/or treatment of organ rejection in patients sensitized to living or cadaveric organ donors
• Schonlein-Henoch
• Treatment of paraneoplastic visual loss
• Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in patients meeting the necessary criteria
• Treatment of multiple myeloma for the prevention of life-threatening infections due to reduced gamma globulins
Summary of evidence (opening)
IVIG has been used for many years in the treatment of immunodeficiency disease. As the knowledge of these diseases has improved and expanded, the use of IVIG has proportionally grown. With this, the body of literature supporting the use of IVIG in these situations has equally grown. The literature supports the use of IVIG in acute situations such as prevention of infections in patients with solid organ and bone marrow transplants, myeloma, leukemia, and HIV infections as well as in the acquired and genetic immunodeficiency syndromes such as CIDP. Additionally, the use in blocking damage by toxic antibodies in Guillain-Barré syndrome, pemphigus and its variants has been shown to be effective.
The contractor cites 30 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2024-04-04
- Last reviewed by the contractor
- 2024-02-27
- MCD version
- 57
- Derived from
- L33761
The contractor lists one National Coverage Determination as related: NCD 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Other related documents: A58289 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L34580 cover?
Intravenous Immune Globulin (IVIG) is a solution of human immunoglobulins specifically prepared for intravenous infusion. Immunoglobulins contain a broad range of antibodies that act specifically against bacterial and viral antigens. The full 374-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L34580 apply to?
Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L34580?
The companion billing and coding article A56718 lists 212 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L34580?
A denial under LCD L34580 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56718's 212 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.